Cargando…

Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning

HER2-positive breast cancer is a highly heterogeneous tumor, and about 30% of patients still suffer from recurrence and metastasis after trastuzumab targeted therapy. Predicting individual prognosis is of great significance for the further development of precise therapy. With the continuous developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jialiang, Ju, Jie, Guo, Lei, Ji, Binbin, Shi, Shufang, Yang, Zixuan, Gao, Songlin, Yuan, Xu, Tian, Geng, Liang, Yuebin, Yuan, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733169/
https://www.ncbi.nlm.nih.gov/pubmed/35035786
http://dx.doi.org/10.1016/j.csbj.2021.12.028
_version_ 1784627741575872512
author Yang, Jialiang
Ju, Jie
Guo, Lei
Ji, Binbin
Shi, Shufang
Yang, Zixuan
Gao, Songlin
Yuan, Xu
Tian, Geng
Liang, Yuebin
Yuan, Peng
author_facet Yang, Jialiang
Ju, Jie
Guo, Lei
Ji, Binbin
Shi, Shufang
Yang, Zixuan
Gao, Songlin
Yuan, Xu
Tian, Geng
Liang, Yuebin
Yuan, Peng
author_sort Yang, Jialiang
collection PubMed
description HER2-positive breast cancer is a highly heterogeneous tumor, and about 30% of patients still suffer from recurrence and metastasis after trastuzumab targeted therapy. Predicting individual prognosis is of great significance for the further development of precise therapy. With the continuous development of computer technology, more and more attention has been paid to computer-aided diagnosis and prognosis prediction based on Hematoxylin and Eosin (H&E) pathological images, which are available for all breast cancer patients undergone surgical treatment. In this study, we first enrolled 127 HER2-positive breast cancer patients with known recurrence and metastasis status from Cancer Hospital of the Chinese Academy of Medical Sciences. We then proposed a novel multimodal deep learning method integrating whole slide H&E images (WSIs) and clinical information to accurately assess the risk of relapse and metastasis in patients with HER2-positive breast cancer. Specifically, we obtained the whole H&E staining images from the surgical specimens of breast cancer patients, and these images were adjusted to size 512 × 512 pixels. The deep convolutional neural network (CNN) was applied to these images to retrieve image features, which were combined with the clinical data. Based on the combined features. After that, a novel multimodal model was constructed for predicting the prognosis of each patient. The model achieved an area under curve (AUC) of 0.76 in the two-fold cross-validation (CV). To further evaluate the performance of our model, we downloaded the data of all 123 HER2-positive breast cancer patients with available H&E image and known recurrence and metastasis status in The Cancer Genome Atlas (TCGA), which was severed as an independent testing data. Despite the huge differences in race and experimental strategies, our model achieved an AUC of 0.72 in the TCGA samples. As a conclusion, H&E images, in conjunction with clinical information and advanced deep learning models, could be used to evaluate the risk of relapse and metastasis in patients with HER2-positive breast cancer.
format Online
Article
Text
id pubmed-8733169
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Research Network of Computational and Structural Biotechnology
record_format MEDLINE/PubMed
spelling pubmed-87331692022-01-13 Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning Yang, Jialiang Ju, Jie Guo, Lei Ji, Binbin Shi, Shufang Yang, Zixuan Gao, Songlin Yuan, Xu Tian, Geng Liang, Yuebin Yuan, Peng Comput Struct Biotechnol J Research Article HER2-positive breast cancer is a highly heterogeneous tumor, and about 30% of patients still suffer from recurrence and metastasis after trastuzumab targeted therapy. Predicting individual prognosis is of great significance for the further development of precise therapy. With the continuous development of computer technology, more and more attention has been paid to computer-aided diagnosis and prognosis prediction based on Hematoxylin and Eosin (H&E) pathological images, which are available for all breast cancer patients undergone surgical treatment. In this study, we first enrolled 127 HER2-positive breast cancer patients with known recurrence and metastasis status from Cancer Hospital of the Chinese Academy of Medical Sciences. We then proposed a novel multimodal deep learning method integrating whole slide H&E images (WSIs) and clinical information to accurately assess the risk of relapse and metastasis in patients with HER2-positive breast cancer. Specifically, we obtained the whole H&E staining images from the surgical specimens of breast cancer patients, and these images were adjusted to size 512 × 512 pixels. The deep convolutional neural network (CNN) was applied to these images to retrieve image features, which were combined with the clinical data. Based on the combined features. After that, a novel multimodal model was constructed for predicting the prognosis of each patient. The model achieved an area under curve (AUC) of 0.76 in the two-fold cross-validation (CV). To further evaluate the performance of our model, we downloaded the data of all 123 HER2-positive breast cancer patients with available H&E image and known recurrence and metastasis status in The Cancer Genome Atlas (TCGA), which was severed as an independent testing data. Despite the huge differences in race and experimental strategies, our model achieved an AUC of 0.72 in the TCGA samples. As a conclusion, H&E images, in conjunction with clinical information and advanced deep learning models, could be used to evaluate the risk of relapse and metastasis in patients with HER2-positive breast cancer. Research Network of Computational and Structural Biotechnology 2021-12-23 /pmc/articles/PMC8733169/ /pubmed/35035786 http://dx.doi.org/10.1016/j.csbj.2021.12.028 Text en © 2021 Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Research Article
Yang, Jialiang
Ju, Jie
Guo, Lei
Ji, Binbin
Shi, Shufang
Yang, Zixuan
Gao, Songlin
Yuan, Xu
Tian, Geng
Liang, Yuebin
Yuan, Peng
Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
title Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
title_full Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
title_fullStr Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
title_full_unstemmed Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
title_short Prediction of HER2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
title_sort prediction of her2-positive breast cancer recurrence and metastasis risk from histopathological images and clinical information via multimodal deep learning
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733169/
https://www.ncbi.nlm.nih.gov/pubmed/35035786
http://dx.doi.org/10.1016/j.csbj.2021.12.028
work_keys_str_mv AT yangjialiang predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT jujie predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT guolei predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT jibinbin predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT shishufang predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT yangzixuan predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT gaosonglin predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT yuanxu predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT tiangeng predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT liangyuebin predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning
AT yuanpeng predictionofher2positivebreastcancerrecurrenceandmetastasisriskfromhistopathologicalimagesandclinicalinformationviamultimodaldeeplearning